Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to David Ross Camidge

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Camidge, David

One or more keywords matched the following items that are connected to Camidge, David

Item Type	Name
Academic Article	A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Academic Article	A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
Academic Article	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Academic Article	Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer.
Academic Article	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Concept	Follow-Up Studies
Academic Article	FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
Academic Article	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Academic Article	Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Academic Article	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Academic Article	Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.
Academic Article	The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.
Academic Article	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Academic Article	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
Academic Article	Radiosurgery alone is associated with favorable outcomes for brain metastases from small-cell lung cancer.
Academic Article	Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.
Academic Article	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
Academic Article	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib?in?Untreated ALK-Positive Advanced Non-Small Cell?Lung Cancer in the Global Phase III ALEX Study.
Academic Article	Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
Academic Article	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Academic Article	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Academic Article	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Academic Article	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Academic Article	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Academic Article	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
Academic Article	Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.

Search Criteria

Follow Up Studies